The first line of treatment for CML is the use of specific tyrosine kinase inhibitors (TKIs) such as imatinib mesylate (IM) that binds to the ATP-binding site of BCR-ABL preventing its conformational switch to the constitutively active form of oncoprotein, and thus causes blockage in uncontrolled proliferation of CML cells [28]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.